The DESTINY-Breast09 study, reported at ASCO, compared antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) and ...

In the ENHERTU arm, the majority of ILD or pneumonitis events were low grade (grade 1 [n=7 ... which represent the first time a HER2 directed medicine has demonstrated a survival benefit in ...

The majority of ILD or pneumonitis events were low grade (grade 1 [n=17 ... “Bringing ENHERTU earlier in the treatment of HER2 positive metastatic breast cancer may represent an important ...

AZ and Daiichi Sankyo already claimed FDA approval for the HER2-low indication in the US last summer, adding to Enhertu's lengthening list of indications, which also includes second- and third ...

Study results unveiled at ASCO show combining Enhertu with Perjeta can significantly delay tumor growth versus a regimen that ...

Enhertu (5.4mg/kg) is approved in more than 80 countries worldwide for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ ISH-) breast cancer who have received ...

Amgen's Nplate, which treats low blood platelet counts caused by an autoimmune condition, was highly effective at preventing ...

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received approval from the US Food and Drug Administration (FDA) for an expanded indication of ...

Trastuzumab deruxtecan improves survival in HER2-low and HER2-ultralow breast cancer ... practice changing data have shown that trastuzumab deruxtecan (Enhertu) can improve survival among patients ...

In the DESTINY-Breast06 trial, the ADC trastuzumab deruxtecan (Enhertu) significantly improved progression-free survival in previously treated metastatic hormone receptor-positive/HER2-low or ...